Completed PHASE4 INTERVENTIONAL 3-arm NCT03192488

Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

Sponsor: Indiana University

Interventions Cetirizine Hypoxia Placebo oral capsule

Updated 8 times since 2017 Last updated: Jun 2, 2020 Started: Aug 31, 2017 Primary completion: Jun 6, 2018 Completion: Jun 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03192488, this PHASE4 trial focuses on Hypoxia, Altitude and remains completed. Sponsored by Indiana University, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jul 2020 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Sep 2019 — Jul 2020 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE4
Sep 2017 — Jun 2018 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Sep 2017 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bloomington, United States